155 results on '"Pandey, Ambarish"'
Search Results
2. Lifetime healthcare expenses across demographic and cardiovascular risk groups: The application of a novel modeling strategy in a large multiethnic cohort study
- Author
-
Khera, Rohan, Kondamudi, Nitin, Liu, Mengni, Ayers, Colby, Spatz, Erica S, Rao, Shreya, Essien, Utibe R, Powell-Wiley, Tiffany M, Nasir, Khurram, Das, Sandeep R, Capers, Quinn, and Pandey, Ambarish
- Published
- 2023
- Full Text
- View/download PDF
3. AHA Life's essential 8 and ideal cardiovascular health among young adults
- Author
-
Shetty, Naman S., Parcha, Vibhu, Patel, Nirav, Yadav, Ishant, Basetty, Chandan, Li, Cynthia, Pandey, Ambarish, Kalra, Rajat, Li, Peng, Arora, Garima, and Arora, Pankaj
- Published
- 2023
- Full Text
- View/download PDF
4. Physical activity, cardiorespiratory fitness, and cardiovascular health: A clinical practice statement of the American Society for Preventive Cardiology Part I: Bioenergetics, contemporary physical activity recommendations, benefits, risks, extreme exercise regimens, potential maladaptations
- Author
-
Franklin, Barry A., Eijsvogels, Thijs M.H., Pandey, Ambarish, Quindry, John, and Toth, Peter P.
- Published
- 2022
- Full Text
- View/download PDF
5. Physical activity, cardiorespiratory fitness, and cardiovascular health: A clinical practice statement of the American Society for Preventive Cardiology Part II: Physical activity, cardiorespiratory fitness, minimum and goal intensities for exercise training, prescriptive methods, and special patient populations
- Author
-
Franklin, Barry A., Eijsvogels, Thijs M.H., Pandey, Ambarish, Quindry, John, and Toth, Peter P.
- Published
- 2022
- Full Text
- View/download PDF
6. Association of disproportionate liver fat with markers of heart failure: The multi-ethnic study of atherosclerosis.
- Author
-
Kusner, Jonathan, Patel, Ravi B., Hu, Mo, Bertoni, Alain G., Michos, Erin D., Pandey, Ambarish, VanWagner, Lisa B., Shah, Sanjiv, and Fudim, Marat
- Abstract
Metabolic dysfunction associated steatotic liver disease (MASLD) has been linked to heart failure with preserved ejection fraction (HFpEF). We sought to understand association between individuals with amounts of liver adiposity greater than would be predicted by their body mass index (BMI) in order to understand whether this disproportionate liver fat (DLF) represents a proxy of metabolic risk shared between liver and heart disease. We studied 2,932 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) who received computed tomography (CT) measurements of hepatic attenuation. Quartiles of DLF were compared and multivariable linear regression was performed to evaluate the association of DLF with clinical, echocardiographic, and quality of life metrics. Compared to the lowest quartile of DLF, individuals in the highest quartile of DLF were more likely to be male (52.0% vs 47.1%, P <.001), less likely to be Black or African American (14.8 % vs 38.1% P <.001), have higher rates of dysglycemia (31.9% vs 16.6%, P <.001) and triglycerides (140 [98.0, 199.0] vs 99.0 [72.0, 144.0] mg/dL, P >.001). These individuals had lower global longitudinal strain (−0.13 [−0.25, −0.02], P =.02), stroke volumes (−1.05 [−1.76, −0.33], P <.01), lateral e' velocity (−0.10 [−0.18, −0.02], P =.02), and 6-minute walk distances (−4.25 [−7.62 to −0.88], P =.01). DLF is associated with abnormal metabolic profiles and ventricular functional changes known to be associated with HFpEF and may serve as an early metric to assess for those that may progress to clinical HFpEF. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Effect of government-issued state of emergency and reopening orders on cardiovascular hospitalizations during the COVID-19 pandemic
- Author
-
Arora, Sameer, Hendrickson, Michael J, Mazzella, Anthony J, Vaduganathan, Muthiah, Chang, Patricia P, Rossi, Joseph S, Qamar, Arman, Pandey, Ambarish, Vavalle, John P, Weickert, Thelsa T, Strassle, Paula D, Yeung, Michael, and Stouffer, George A
- Published
- 2021
- Full Text
- View/download PDF
8. County-level phenomapping to identify disparities in cardiovascular outcomes: An unsupervised clustering analysis: Short title: Unsupervised clustering of counties and risk of cardiovascular mortality
- Author
-
Segar, Matthew W., Rao, Shreya, Navar, Ann Marie, Michos, Erin D., Lewis, Alana, Correa, Adolfo, Sims, Mario, Khera, Amit, Hughes, Amy E., and Pandey, Ambarish
- Published
- 2020
- Full Text
- View/download PDF
9. Intraosseous versus intravenous access in patients with out-of-hospital cardiac arrest: Insights from the resuscitation outcomes consortium continuous chest compression trial
- Author
-
Mody, Purav, Brown, Siobhan P., Kudenchuk, Peter J., Chan, Paul S., Khera, Rohan, Ayers, Colby, Pandey, Ambarish, Kern, Karl B., de Lemos, James A., Link, Mark S., and Idris, Ahamed H.
- Published
- 2019
- Full Text
- View/download PDF
10. National Variation in Hospital MTEER Outcomes and Correlation With TAVR Outcomes: STS/ACC TVT Registry Analysis.
- Author
-
Kumbhani, Dharam J., Manandhar, Pratik, Bavry, Anthony A., Chhatriwalla, Adnan K., Giri, Jay, Mack, Michael, Carroll, John, Pandey, Ambarish, Kosinski, Andrzej, Peterson, Eric D., Kaneko, Tsuyoshi, de Lemos, James A., and Vemulapalli, Sreekanth
- Abstract
A single, multitiered valve center designation has been proposed to publicly identify centers with expertise for all valve therapies. The correlation between transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER) procedures is unknown. The authors sought to examine the relationship between site-level volumes and outcomes for TAVR and MTEER. We further explored variability between sites for MTEER outcomes. Using the STS/ACC TVT (Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy) national registry, TAVR and MTEER procedures at sites offering both therapies from 2013 to 2022 were examined. Sites were ranked into deciles of adjusted in-hospital and 30-day outcomes separately for TAVR and MTEER and compared. Stepwise, hierarchical multivariable models were constructed for MTEER outcomes, and the median OR was calculated. Between 2013 and 2022, 384,394 TAVRs and 53,274 MTEERs (median annualized volumes: 93.6 and 18.8, respectively) were performed across 453 U.S. sites. Annualized TAVR and MTEER volumes were moderately correlated (r = 0.48; P < 0.001). After adjustment, 14.3% of sites had the same decile rank for TAVR and MTEER 30-day composite outcome, 50.6% were within 2 decile ranks; 35% had more discordant outcomes for the 2 procedures (P = 0.0005). For MTEER procedures, the median OR for the 30-day composite outcome was 1.57 (95% CI: 1.51-1.64), indicating a 57% variability in outcome by site. There is modest correlation between hospital-level volumes for TAVR and MTEER but low interprocedural correlation of outcomes. For similar patients, site-level variability for mortality/morbidity following MTEER was high. Factors influencing outcomes and "centers of excellence" as a whole may differ for TAVR and MTEER. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Temporal trends and racial/ethnic- and sex-differences in LDL cholesterol control among US adults with self-reported atherosclerotic cardiovascular disease
- Author
-
Nguyen, Danh Q., Keshvani, Neil, Chandra, Alvin, Alebna, Pamela L., Dixon, Dave L., Shapiro, Michael D., Michos, Erin D., Sperling, Laurence S., Pandey, Ambarish, and Mehta, Anurag
- Published
- 2024
- Full Text
- View/download PDF
12. Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015–2020
- Author
-
Jacobs, Joshua A., Zheutlin, Alexander R., Derington, Catherine G., King, Jordan B., Pandey, Ambarish, and Bress, Adam P.
- Published
- 2024
- Full Text
- View/download PDF
13. Role of exercise therapy and cardiac rehabilitation in heart failure.
- Author
-
Patel, Lajjaben, Dhruve, Ritika, Keshvani, Neil, and Pandey, Ambarish
- Abstract
Heart failure (HF) is a common cause of hospitalization and death, and the hallmark symptoms of HF, including dyspnea, fatigue, and exercise intolerance, contribute to poor patient quality of life (QoL). Cardiac rehabilitation (CR) is a comprehensive disease management program incorporating exercise training, cardiovascular risk factor management, and psychosocial support. CR has been demonstrated to effectively improve patient functional status and QoL among patients with HF. However, CR participation among patients with HF is poor. This review details the mechanisms of dyspnea and exercise intolerance among patients with HF, the physiologic and clinical improvements observed with CR, and the key components of a CR program for patients with HF. Furthermore, unmet needs and future strategies to improve patient participation and engagement in CR for HF are reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Racial differences in low natriuretic peptide levels: Implications for heart failure clinical trials.
- Author
-
Gangavelli, Apoorva, Liu, Zihao, Wang, Jeffrey, Okoh, Alexis, Steinberg, Rebecca, Patel, Krishan, Pandey, Ambarish, Gupta, Deepak K., Dickert, Neal, Patel, Shivani A., and Morris, Alanna A.
- Abstract
Some patients with heart failure (HF) have low natriuretic peptide (NP) levels. It is unclear whether specific populations are disproportionately excluded from participation in randomized clinical trials (RCT) with inclusion requirements for elevated NPs. We investigated factors associated with unexpectedly low NP levels in a cohort of patients hospitalized with HF, and the implications on racial diversity in a prototype HF RCT. We created a retrospective cohort of 31,704 patients (age 72 ± 16 years, 49% female, 52% Black) hospitalized with HF from 2010 to 2020 with B-type natriuretic peptide (BNP) measurements. Factors associated with unexpectedly low BNP levels (<50 pg/mL) were identified using multivariable logistic regression models. We simulated patient eligibility for a prototype HF trial using specific inclusion and exclusion criteria, and varying BNP cut-offs. Unexpectedly low BNP levels were observed in 8.9% of the cohort. Factors associated with unexpectedly low BNP levels included HFpEF (aOR 3.76, 95% CI: 3.36, 4.20), obesity (aOR 1.96, 95% CI: 1.73, 2.21), self-identification as Black (aOR 1.53, 95% CI: 1.36, 1.71), and male gender (aOR 1.45, 95% CI: 1.31, 1.60). Applying limited clinical inclusion and exclusion criteria from PARAGLIDE-HF disproportionately excluded Black patients, with impairment in renal function having the greatest impact. Adding thresholds for BNP of ≥35, ≥50, ≥67, ≥100, and ≥150 pg/mL demonstrated the risk of exclusion was higher for Black compared to non-Black patients (RR = 2.03 [95% CI: 1.73, 2.39], 1.90 [95% CI: 1.68, 2.15], 1.63 [95% CI: 1.48, 1.81], 1.38 [95% CI: 1.28, 1.50], and 1.23 [95% CI: 1.15, 1.31], respectively). Nearly 10% of patients hospitalized with HF have unexpectedly low BNP levels. Simulating inclusion into a prototype HFpEF RCT demonstrated that requiring increasingly elevated NP levels disproportionately excludes Black patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. RELATIONSHIP BETWEEN SOCIOECONOMIC STATUS, CORONARY ARTERY CALCIUM AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: A MULTI-COHORT STUDY
- Author
-
Triana, Taylor, Berlacher, Mark, Watson, Karol, Ayers, Colby, Wu, Elaine, Rao, Shreya, Powell-Wiley, Tiffany M., Pandey, Ambarish, Joshi, Parag, Bancks, Michael P, Blaha, Michael, Budoff, Matthew, and Khera, Amit
- Published
- 2023
- Full Text
- View/download PDF
16. SOCIAL DETERMINANTS IN A LOW-INCOME POPULATION WITH HEART FAILURE
- Author
-
Lokesh, Nidhish, Nagori, Aditya, Keshvani, Neil, Pandey, Ambarish, and Sumarsono, Andrew
- Published
- 2023
- Full Text
- View/download PDF
17. Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society.
- Author
-
Yeung, Andrea M., Huang, Jingtong, Pandey, Ambarish, Hashim, Ibrahim A., Kerr, David, Pop-Busui, Rodica, Rhee, Connie M., Shah, Viral N., Bally, Lia, Bayes-Genis, Antoni, Bee, Yong Mong, Bergenstal, Richard, Butler, Javed, Fleming, G. Alexander, Gilbert, Gregory, Greene, Stephen J., Kosiborod, Mikhail N., Leiter, Lawrence A., Mankovsky, Boris, and Martens, Thomas W.
- Abstract
Diabetes Technology Society assembled a panel of clinician experts in diabetology, cardiology, clinical chemistry, nephrology, and primary care to review the current evidence on biomarker screening of people with diabetes (PWD) for heart failure (HF), who are, by definition, at risk for HF (Stage A HF). This consensus report reviews features of HF in PWD from the perspectives of 1) epidemiology, 2) classification of stages, 3) pathophysiology, 4) biomarkers for diagnosing, 5) biomarker assays, 6) diagnostic accuracy of biomarkers, 7) benefits of biomarker screening, 8) consensus recommendations for biomarker screening, 9) stratification of Stage B HF, 10) echocardiographic screening, 11) management of Stage A and Stage B HF, and 12) future directions. The Diabetes Technology Society panel recommends 1) biomarker screening with one of two circulating natriuretic peptides (B-type natriuretic peptide or N-terminal prohormone of B-type natriuretic peptide), 2) beginning screening five years following diagnosis of type 1 diabetes (T1D) and at the diagnosis of type 2 diabetes (T2D), 3) beginning routine screening no earlier than at age 30 years for T1D (irrespective of age of diagnosis) and at any age for T2D, 4) screening annually, and 5) testing any time of day. The panel also recommends that an abnormal biomarker test defines asymptomatic preclinical HF (Stage B HF). This diagnosis requires follow-up using transthoracic echocardiography for classification into one of four subcategories of Stage B HF, corresponding to risk of progression to symptomatic clinical HF (Stage C HF). These recommendations will allow identification and management of Stage A and Stage B HF in PWD to prevent progression to Stage C HF or advanced HF (Stage D HF). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.
- Author
-
Tsutsui, HIROYUKI, ALBERT, NANCY M., COATS, ANDREW J.S., ANKER, STEFAN D., BAYES-GENIS, ANTONI, BUTLER, JAVED, CHIONCEL, OVIDIU, DEFILIPPI, CHRISTOPHER R., DRAZNER, MARK H., FELKER, G. MICHAEL, FILIPPATOS, GERASIMOS, FIUZAT, MONA, IDE, TOMOMI, JANUZZI, JAMES L., KINUGAWA, KOICHIRO, KUWAHARA, KOICHIRO, MATSUE, YUYA, MENTZ, ROBERT J., METRA, MARCO, and PANDEY, AMBARISH
- Abstract
Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (HF). In addition, they can have an important complementary role in the risk stratification of its prognosis. Since the development of angiotensin receptor neprilysin inhibitors (ARNIs), the use of natriuretic peptides as therapeutic agents has grown in importance. The present document is the result of the Trilateral Cooperation Project among the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America and the Japanese Heart Failure Society. It represents an expert consensus that aims to provide a comprehensive, up-to-date perspective on natriuretic peptides in the diagnosis and management of HF, with a focus on the following main issues: (1) history and basic research: discovery, production and cardiovascular protection; (2) diagnostic and prognostic biomarkers: acute HF, chronic HF, inclusion/endpoint in clinical trials, and natriuretic peptides-guided therapy; (3) therapeutic use: nesiritide (BNP), carperitide (ANP) and ARNIs; and (4) gaps in knowledge and future directions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Inconsistent Outcome Reporting in Heart Failure Randomized Controlled Trials.
- Author
-
SIDDIQI, TARIQ JAMAL, SHAHID, IZZA, ARSHAD, MUHAMMAD SAMEER, GREENE, STEPHEN J., PANDEY, AMBARISH, VADUGANATHAN, MUTHIAH, VAN SPALL, HARRIETTE G.C., MENTZ, ROBERT J., FONAROW, GREGG C., and KHAN, MUHAMMAD SHAHZEB
- Abstract
• More than 1 in 10 trials reported outcomes inconsistent with those prespecified. • The majority of the inconsistencies favored statistically significant findings. • Single-center recruitment was associated with inconsistent outcome reporting. Randomized controlled trials (RCTs) may report outcomes different from those prespecified on trial-registration websites, protocols and statistical analysis plans (SAPs). This study sought to investigate the prevalence and characteristics of heart failure (HF) RCTs that report outcomes different from those prespecified. MEDLINE via PubMed was searched to include phase II–IV HF RCTs in 9 high-impact journals from 2010 to 2020. Outcomes reported in trial publications were compared with prespecified outcomes in protocols, registration websites and SAPs. We used the χ
2 or Fisher exact test to analyze correlations between trial characteristics and inconsistencies. Among 216 trials, 32 inconsistencies were observed in 28 trials (13.0%). Among 32 inconsistencies, 2 (6.3%) pertained to omission of prespecified primary outcomes, 4 (12.5%) to omission of prespecified secondary outcomes, 2 (6.3%) to changing prespecified primary outcomes to secondary outcomes, and 2 (6.3%) to changing prespecified secondary outcomes to primary outcomes. Of the inconsistencies, 3 (9.4%) pertained to addition of new primary outcomes, 17 (53.1%) to addition of new secondary outcomes, and 2 (6.3%,) to changes in the timing of assessment of primary outcomes. The majority of the inconsistencies favored statistically significant findings; 78 (36.1%) were registered retrospectively. Single-center recruitment was associated with outcome inconsistencies (β = -0.14; 95% CI, -0.22 – -0.01; P = 0.035). More than 1 in 10 trials reported outcomes inconsistent with those specified in trial registration websites, SAPs and protocols. An action plan is warranted to minimize selective reporting and improve transparency. [Display omitted] [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
20. Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults.
- Author
-
Saha, Amit, Patel, Kershaw V., Ayers, Colby, Ballantyne, Christie M., Correa, Adolfo, Defilippi, Christopher, Hall, Michael E., Mentz, Robert J., Seliger, Stephen L., Yimer, Wondwosen, Butler, Javed, Berry, Jarett D., De Lemos, James A., and Pandey, Ambarish
- Abstract
• Among Black adults, one-quarter had new or stable elevated troponin on follow-up. • Incident elevation in troponin was associated with a higher risk of heart failure. • Stable or worsened elevated troponin was associated with a higher heart failure risk. Among Black adults, high-sensitivity cardiac troponin I (hs-cTnI) is associated with heart failure (HF) risk. The association of longitudinal changes in hs-cTnI with risk of incident HF, HF with reduced and preserved ejection fraction (HFrEF and HFpEF, respectively), among Black adults is not well-established. This study included Black participants from the Jackson Heart Study with available hs-cTnI data at visits 1 (2000–2004) and 2 (2005–2008) and no history of cardiovascular disease. Cox models were used to evaluate associations of categories of longitudinal change in hs-cTnI with incident HF risk. Among 2423 participants, 11.6% had incident elevation in hs-cTnI at visit 2, and 16.9% had stable or improved elevation (≤50% increase in hs-cTnI), and 4.0% had worsened hs-cTnI elevation (>50% increase). Over a median follow-up of 12.0 years, there were 139 incident HF hospitalizations (64 HFrEF, 58 HFpEF). Compared with participants without an elevated hs-cTnI, those with incident, stable or improved, or worsened hs-cTnI elevation had higher HF risk (adjusted hazard ratio 3.20 [95% confidence interval, 1.92–5.33]; adjusted hazard ratio 2.40, [95% confidence interval, 1.47–3.92]; and adjusted hazard ratio 8.10, [95% confidence interval, 4.74–13.83], respectively). Similar patterns of association were observed for risk of HFrEF and HFpEF. Among Black adults, an increase in hs-cTnI levels on follow-up was associated with a higher HF risk. The present study included 2423 Black adults from the Jackson Heart Study with available biomarkers of cardiac injury and no history of cardiovascular disease at visits 1 and 2. The majority of participants did not have evidence of cardiac injury at both visits (67.5%), 11.6% had evidence of cardiac injury only on follow-up, 14.5% had stable elevations, 4.0% had worsened elevations, and 2.4% had improved elevations of cardiac injury biomarkers during follow-up. Compared with participants without evidence of cardiac injury, those with new, stable, and worsened levels of cardiac injury had a higher risk of developing heart failure. Among Black adults, persistent or worsening subclinical myocardial injury is associated with an elevated risk of HF. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Glycemic Markers and Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA).
- Author
-
Echouffo-Tcheugui, JUSTIN B., OGUNMOROTI, OLUSEYE, GOLDEN, SHERITA H., BERTONI, ALAIN G., MONGRAW-CHAFFIN, MORGANA, PANDEY, AMBARISH, NDUMELE, CHIADI E., and MICHOS, ERIN D.
- Abstract
Background: Although diabetes increases heart failure (HF) risk, it is unclear how various dysglycemia markers (hemoglobin A1C [HbA1C], fasting plasma glucose [FPG], homeostasis model assessment of insulin resistance, and fasting insulin) are associated with HF subtypes (HF with preserved ejection fraction [HFpEF] and HF with reduced ejection fraction [HFrEF]). We assessed the relation of markers of dysglycemia and risks of HFpEF and HFrEF.Methods and Results: We included 6688 adults without prevalent cardiovascular disease who attended the first MESA visit (2000-2002) and were followed for incident hospitalized HF (HFpEF or HFrEF). Association of glycemic markers and status (normoglycemia, prediabetes, diabetes) with HFpEF and HFrEF were evaluated using adjusted Cox models. Over a median follow-up of 14.9 years, there were 356 HF events (145 HFpEF, 173 HFrEF, and 38 indeterminate HF events). Diabetes status conferred higher risks of HFpEF (hazard ratio [HR] 1.85, 95% confidence interval [CI] 1.57-2.68) and HFrEF (HR 2.02, 95% CI 1.38-2.97) compared with normoglycemia. Higher levels of FPG (≥126 mg/dL) and HbA1C (≥6.5%) were associated with similarly higher risks of HFpEF (HR for FPG 1.96, 95% CI 1.21-3.17; HR for HbA1C 2.00, 95% CI 1.20-3.31) and HFrEF (HR for FPG 1.84, 95% CI 1.18-2.88; HR for HbA1C 1.99, 95% CI 1.28-3.09) compared with reference values. Prediabetic range HbA1C (5.7%-6.4%) or FPG (100%-125 mg/dL), homeostasis model assessment of insulin resistance, and fasting insulin were not significantly associated with HFpEF or HFrEF.Conclusions: Among community-dwelling individuals, HbA1C and FPG in the diabetes range were each associated with higher risks of HFpEF and HFrEF, with similar magnitudes of their associations.Lay Abstract: Heart failure (HF) has 2 major subtypes (the heart's inability to pump or to fill up). Diabetes is known to increase HF risk, but its effects and that of markers of high glucose levels (fasting blood glucose and hemoglobin A1C) on the occurrence of HF subtypes remains unknown. Among 6688 adults without known cardiovascular disease followed for nearly 15 years, diabetes conferred significantly higher risks of both HF types, compared with those with normal blood glucose levels. Higher levels of fasting blood glucose and hemoglobin A1C were similarly associated with higher risks of both types of HF. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
22. 3177 – CLONAL HEMATOPOIESIS PROMOTES HEART FAILURE WITH PRESERVED EJECTION FRACTION.
- Author
-
Thomas, Toby, Pandey, Ambarish, Ji, Yuanyuan, Kroger, Benjamin, Irion, Camila, Kalkan, Fatma, Segar, Matthew, Subramanian, Vinayak, Genis, Antonio, Hu, Wenhuo, Son, Albert, Carlsgaard, Peter, Premnath, Naveen, Jiang, Nan, Daou, Daniel, Ware, Sarah, Tong, Dan, and Chung, Stephen
- Subjects
- *
NITRIC-oxide synthases , *HIGH-fat diet , *BONE marrow , *VENTRICULAR ejection fraction , *LABORATORY mice , *HEART failure - Abstract
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure, but its etiology is poorly understood. Clonal hematopoiesis (CH) has been shown to promote atherosclerosis and heart failure with reduced ejection fraction, but whether and how CH may promote HFpEF is less well understood. We screened for CH in 109 HFpEF patients at UTSW and identified CH in 25% of patients, as compared with 19% of age/gender-matched controls. The most frequent mutation was in TET2 (63%), and notably 42% of patients with TET2-mutated CH harbored two TET2 mutations. In contrast, mutations in DNMT3A, classically the most frequent mutation in age-associated CH, were present at a much lower rate (30%). To test if TET2-mutated CH promotes HFpEF, we used a mouse model in which a high-fat diet and nitric oxide synthase inhibition by L-NAME recapitulate the clinical features of HFpEF (Nature 2019;568:351). We transplanted pIpC-treated bone marrow from Mx1-Cre;Tet2fl/fl mice or Cre-negative Tet2fl/fl control mice into wild-type mice, and six weeks later we induced HFpEF for 12 weeks. Consistent with our clinical observations, we discovered that recipients of Tet2-null hematopoietic cells exhibited significantly worse diastolic dysfunction. This effect was dependent on the NLRP3 inflammasome and was specific to loss of Tet2, while mice transplanted with Dnmt3a-null bone marrow did not manifest a worse HFpEF phenotype. Additionally, bulk and single-cell transcriptomic analyses revealed that HFpEF induction led to an expansion in the heart of Spp1+ macrophages, which exhibit both pro-inflammatory and pro-fibrotic features, which was exacerbated in the setting of CH. In sum, TET2-mutated CH is common in patients with HFpEF and drives disease pathogenesis in an allele-specific manner. These findings establish a rationale for targeting CH to treat or prevent HFpEF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Corrigendum to U.S. Population at Increased Risk of Severe Illness from COVID-19
- Author
-
Ajufo, Ezimamaka, Rao, Shreya, Navar, Ann Marie, Pandey, Ambarish, Ayers, Colby R., and Khera, Amit
- Published
- 2021
- Full Text
- View/download PDF
24. Hypertension guidelines and coronary artery calcification among South Asians: Results from MASALA and MESA
- Author
-
Patel, Jaideep, Mehta, Anurag, Rifai, Mahmoud Al, Blaha, Michael J, Nasir, Khurram, McEvoy, John W, Pandey, Ambarish, Kanaya, Alka M, Kandula, Namratha R, Virani, Salim S, Abbate, Antonio, Hundley, Gregory, Sperling, Laurence, and Joshi, Parag H
- Published
- 2021
- Full Text
- View/download PDF
25. U.S. population at increased risk of severe illness from COVID-19
- Author
-
Ajufo, Ezimamaka, Rao, Shreya, Navar, Ann Marie, Pandey, Ambarish, Ayers, Colby R., and Khera, Amit
- Published
- 2021
- Full Text
- View/download PDF
26. The Future of AI-Enhanced ECG Interpretation for Valvular Heart Disease Screening.
- Author
-
Pandey, Ambarish and Adedinsewo, Demilade
- Subjects
- *
HEART valve diseases , *MEDICAL screening , *ELECTROCARDIOGRAPHY , *AORTIC stenosis , *ARTIFICIAL intelligence - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study.
- Author
-
Chunawala, Zainali S., Qamar, Arman, Arora, Sameer, Pandey, Ambarish, Fudim, Marat, Vaduganathan, Muthiah, Bhatt, Deepak L., Mentz, Robert J., and Caughey, Melissa C.
- Abstract
Background: Polyvascular disease is associated with increased mortality rates and decreased quality of life. Whether its prevalence or associated outcomes differ for patients hospitalized with heart failure with reduced vs preserved ejection fraction (HFrEF vs HFpEF, respectively) is uncertain.Methods: The Atherosclerosis Risk in Communities (ARIC) study conducted hospital surveillance of acute decompensated heart failure (ADHF) from 2005-2014. Polyvascular disease (coexisting disease in ≥ 2 arterial beds) was identified based on the finding of prevalent coronary artery disease, peripheral artery disease or cerebrovascular disease. Mortality risks associated with polyvascular disease were analyzed separately for HFpEF and HFrEF, with adjustment for potential confounders. All analyses were weighted by the inverse of the sampling probability.Results: Of 24,937 weighted (5460 unweighted) hospitalizations due to ADHF (52% female, 32% Black, mean age 75 years), polyvascular disease was prevalent in 22% with HFrEF and in 17% with HFpEF. One-year mortality risks increased sequentially with 0, 1 and ≥ 2 arterial bed involvement, both for patients with HFrEF (29%-32%-38%; P trend = 0.0006) and for those with HFpEF (26%-32%-37%; P trend < 0.0001). After adjustments, polyvascular disease was associated with a 26% higher mortality hazard for patients with HFrEF (HR = 1.26; 95% CI: 1.07-1.50) and a 29% higher hazard for patients with HFpEF (HR = 1.29; 95% CI: 1.03-1.62), with no interaction by HF type (P interaction = 0.9).Conclusion: Patients hospitalized with ADHF and coexisting polyvascular disease have an increased risk of death, irrespective of HF type. Clinical attention should be directed toward polyvascular disease, with implementation of secondary prevention strategies to improve the prognosis of this high-risk population.Summary: Polyvascular disease is known to be associated with myocardial infarction, stroke or cardiovascular death and is a major risk factor for decreased quality of life. This study sought to evaluate the relationship between polyvascular disease and mortality in patients hospitalized with acute decompensated heart failure (ADHF), and to understand whether the associations differ based on ejection fraction. Patients hospitalized with ADHF and coexisting polyvascular disease had an increased risk of death, irrespective of heart failure type, implying the need for increased clinical attention directed toward polyvascular disease, along with implementation of secondary prevention strategies to improve prognosis.Tweet: Patients hospitalized with acute HF and coexisting polyvascular disease face an increased risk of death, irrespective of HF type. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
28. Phenomapping chest pain: analyses from the PROMISE and ROMICAT-II cohorts
- Author
-
Segar, Matthew W., Patel, Kershaw, Raygor, Viraj, Vigen, Rebecca, and Pandey, Ambarish
- Published
- 2020
- Full Text
- View/download PDF
29. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials.
- Author
-
Rao, Shreya, Jamal Siddiqi, Tariq, Khan, Muhammad Shahzeb, Michos, Erin D., Navar, Ann Marie, Wang, Thomas J., Greene, Stephen J., Prabhakaran, Dorairaj, Khera, Amit, and Pandey, Ambarish
- Abstract
Prior studies have reported improvements in population-level risk factor burden and cardiovascular disease (CVD) outcomes using polypills for CVD risk reduction. However, a comprehensive assessment of the impact of polypills on CVD outcomes, mortality, adherence, and side effects across different settings has not previously been reported. We performed a systematic review and meta-analysis of randomized controlled trials examining the association between polypill therapy and CVD outcomes published before February 2021. The primary outcome of interest was the risk of major adverse CVD events (MACE). Risk ratios for dichotomous outcomes were converted to log RR and pooled using a generic inverse variance weighted random-effects model. Data for continuous outcomes were pooled using random-effects modeling and presented as mean differences with 95% CIs. Eight studies representing 25,584 patients were included for analysis. In the overall pooled analysis, the use of polypills was associated with a non-significant reduction in the risk of MACE (RR: 0.85; 95% CI: 0.70-1.02) and significant reductions in the risk of all-cause mortality (RR: 0.90; 95% CI: 0.81-1.00). The reductions in the risk of MACE with polypill use varied by baseline risk and nature of the study population (primary prevention vs. secondary prevention), with the most significant risk reduction among lower-risk cohorts, including within primary prevention populations [RR 0.70 (0.62, 0.79)]. Among measures of CVD risk factors, modest but significant reductions were observed for systolic and diastolic blood pressure [systolic: mean difference 1.99 mmHg (95% CI: -3.07 to -0.91); diastolic: mean difference 1.30 mmHg (95% CI: -2.42 to -0.19), but not for levels of total or low-density lipoprotein-cholesterol. Use of the polypill strategy significantly improved drug adherence (RR: 1.31; 95% CI: 1.11-1.55) with no association between polypill use and rates of adverse events or drug discontinuation. The use of polypill formulations is associated with significant reductions in CVD risk factors and the risk of all-cause mortality and MACE, particularly in the low-risk and primary prevention population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. Forecasting Heart Failure Risk in Diabetes.
- Author
-
Verma, Subodh, Pandey, Ambarish, and Bhatt, Deepak L.
- Subjects
- *
HEART failure , *DIABETES , *FORECASTING , *RISK assessment - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. The Relationship Between Atrial Fibrillation, Mitral Regurgitation, and Heart Failure Subtype: The ARIC Study.
- Author
-
Arora, Sameer, Brown, Zachary D., Sivaraj, Krishan, Hendrickson, Michael J., Mazzella, Anthony J., Chang, Patricia P., Vaduganathan, Muthiah, Qamar, Arman, Gehi, Anil K., Pandey, Ambarish, and Vavalle, John P.
- Abstract
Background: Atrial fibrillation (AF) and mitral regurgitation (MR) are closely interrelated in the setting of heart failure (HF). Here we investigate the prevalence and prognostic significance of AF in patients with acute decompensated HF (ADHF) stratified by MR severity.Methods and Results: The Atherosclerosis Risk in Communities Study investigated ADHF hospitalizations in residents greater than or equal to 55 years of age in 4 US communities. ADHF cases were stratified by MR severity (none/mild or moderate/severe) and HF subtype (HF with reduced [HFrEF] or preserved [HFpEF] ejection fraction). The odds of AF in patients with increasing MR severity was estimated using multivariable logistic regression, adjusting for age, race, sex, diabetes, hypertension, coronary artery disease, hemodialysis, stroke, and anemia. Cox regression models were used to assess the association of AF with 1-year mortality in patients with HFpEF and HFrEF, stratified by MR severity and adjusted as described, also adjusting for the year of hospitalization. From 2005 to 2014, there were 3,878 ADHF hospitalizations (17,931 weighted). AF was more likely in those with higher MR severity regardless of HF subtype; more so in HFpEF (odds ratio [OR] 1.38, 95% confidence interval [CI], 1.31-1.45) than in HFrEF (OR, 1.19, 95% CI, 1.13-1.25) (interaction P [by HF subtype] < .01). When stratified by HF type, association between AF and 1-year mortality was noted in patients with HFpEF (OR, 1.28, 95% CI 1.04-1.56) but not HFrEF (OR 0.96, 95% CI 0.79-1.16) (interaction by EF subtype, P = .02).Conclusions: In patients with ADHF, AF prevalence increased with MR severity and this effect was more pronounced in HFpEF compared with HFrEF. AF was associated with an increased 1-year mortality only in patients with HFpEF and concomitant moderate/severe MR.Registration: NCT00005131, https://clinicaltrials.gov/ct2/show/NCT00005131. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
32. Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines - heart failure participating centers.
- Author
-
Patel, Kershaw V., Keshvani, Neil, Pandey, Ambarish, Vaduganathan, Muthiah, Holmes, DaJuanicia N., Matsouaka, Roland A., DeVore, Adam D., Allen, Larry A., Yancy, Clyde W., and Fonarow, Gregg C.
- Abstract
Background: The Hospital Readmissions Reduction Program penalizes hospitals with excess 30-day risk-standardized readmission rates (RSRR) for heart failure (HF). The association of financial penalty amount with subsequent short-term clinical outcomes is unknown.Methods: Patients admitted to American Heart Association Get With The Guidelines-HF registry participating centers from October 1, 2012 through December 1, 2015 who had Medicare-linked data were included. October 2012 hospital-specific penalty amounts were calculated based on diagnosis-related group payments and excess readmission ratios. Adjusted Cox models were created to evaluate the association of penalty amount categories (non-penalized: 0%; low-penalized: >0%-<0.50%; mid-penalized ≥0.50%-<0.99%; high-penalized ≥0.99%) with subsequent 30-day RSRR and risk-standardized mortality rates (RSMR). Trends in post-discharge 30-day RSRR and RSMR from 2012 to 2015 were analyzed across hospitals stratified by penalty amount categories.Results: The present study included 61,329 patients who were admitted across 262 hospitals. Compared with patients admitted to non-penalized hospitals (36.3%), those admitted to increasingly penalized hospitals were more likely to have higher 30-day RSRR (low-penalized [43.9%]: HR, 1.10 [95% CI, 1.04-1.16]; mid-penalized [12.0%]: HR, 1.07 [95% CI, 0.99-1.16]; high-penalized [7.9%]: HR, 1.23 [95% CI, 1.12-1.35]) but not 30-day RSMR. Over time, 30-day RSRR and RSMR did not meaningfully change across penalized versus non-penalized hospitals.Conclusions: Financial penalties based on 30-day RSRR are not associated with declines in 30-day RSRR or RSMR from 2012 to 2015 among patients hospitalized with HF. Financially penalizing hospitals based on current Hospital Readmissions Reduction Program metrics may not incentivize improvements in short-term clinical outcomes for HF. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
33. Guideline based eligibility for primary prevention statin therapy – Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI).
- Author
-
Arora, Sameer, Qamar, Arman, Gupta, Puneet, Hendrickson, Michael, Singh, Avinainder, Vaduganathan, Muthiah, Pandey, Ambarish, Bansal, Ankit, Batra, Vishal, Mukhopadhyay, Saibal, Yusuf, Jamal, Tyagi, Sanjay, Girish, MP, Kaul, Prashant, Bhatt, Deepak L., and Gupta, Mohit
- Subjects
STATINS (Cardiovascular agents) ,CARDIOVASCULAR diseases risk factors ,AGE distribution ,ST elevation myocardial infarction ,MEDICAL protocols ,RISK assessment ,ELIGIBILITY (Social aspects) ,CORONARY artery disease ,DISEASE risk factors - Abstract
• Asian Indians are having a cardiovascular event at a very early age. • Pooled Cohort Equations are inadequate to assess this population. • Traditional risk factors cannot fully explain the higher events in young subjects. • Certain limitations of the study provide possible insights for future research. Current risk scores to estimate atherosclerotic cardiovascular disease (ASCVD) risk and allocate statins in at-risk persons have largely been developed in Western populations; their applicability in India is uncertain. To assess eligibility for primary prevention statin therapy using the 2018 U.S Multisociety Guideline and other contemporary cholesterol guidelines in patients presenting with ST-elevation myocardial infarction (STEMI) in the North India STEMI (NORIN-STEMI) registry. NORIN-STEMI registry prospectively enrolled 3,635 patients at 2 tertiary care centers in Delhi, India from January 2019 to February 2020. Pooled cohort risk equations were used to estimate ASCVD risk at presentation. Patients were evaluated for statin eligibility using the 2018 U.S Multisociety Guideline, United States Preventive Services Task Force (USPSTF), and National Cholesterol Education Program (NCEP) III cholesterol guidelines. A total of 2,551 met the inclusion criteria. The median age was 54 years; 17% were women. The median ASCVD risk was 7.0%. At the time of MI, 54% of patients were eligible for primary prevention statin therapy by Multisociety Guideline, 46% by USPSTF, and 30% by NCEP III guidelines. These findings were applicable in both women and men. Compared with patients aged ≥50 years, those <50 years were less likely to be recommended statin therapy by all the three guidelines. A significant proportion of patients with STEMI in India did not meet the current guideline-based threshold for statin therapy for primary prevention. Novel risk stratification tools are needed to identify patients for primary prevention statin therapy in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.
- Author
-
Kozlitina, Julia, Garg, Sonia, Drazner, Mark H., Matulevicius, Susan A., Ayers, Colby, Overton, John, Reid, Jeffrey, Baras, Aris, Rao, Krishnasree, Pandey, Ambarish, Berry, Jarett, de Lemos, James A., and Grodin, Justin L.
- Abstract
Background: The V122I variant in transthyretin (TTR) is the most common amyloidogenic mutation worldwide. The aim of this study is to describe the cardiac phenotype and risk for adverse cardiovascular outcomes of young V122I TTR carriers in the general population.Methods and Results: TTR genotypes were extracted from whole-exome sequence data in participants of the Dallas Heart Study. Participants with African ancestry, available V122I TTR genotypes (N = 1818) and either cardiac magnetic resonance imaging (n = 1364) or long-term follow-up (n = 1532) were included. The prevalence of V122I TTR carriers (45 ± 10 years) was 3.2% (n/N = 59/1818). The V122I TTR carriers had higher baseline left ventricular wall thickness (8.52 ± 1.82 vs 8.21 ± 1.62 mm, adjusted P = .038) than noncarriers, but no differences in other cardiac magnetic resonance imaging measures (P > .05 for all). Although carrier status was not associated with amino terminal pro-B-type natriuretic peptide (NT-proBNP) at baseline (P = .79), V122I TTR carriers had a greater increase in NT-proBNP on follow-up than noncarriers (median 28.5 pg/mL, interquartile range 11.4-104.1 pg/mL vs median 15.9 pg/mL, interquartile range 0.0-43.0 pg/mL, adjusted P = .018). V122I TTR carriers were at a higher adjusted risk of heart failure (hazard ratio 3.82, 95% confidence interval 1.80-8.13, P < .001), cardiovascular death (hazard ratio 2.65, 95% confidence interval 1.14-6.15, P = .023), and all-cause mortality (hazard ratio 1.95, 95% confidence interval 1.08-3.51, P = .026) in comparison with noncarriers.Conclusions: V122I TTR carrier status was associated with a greater increase in NT-proBNP, slightly greater left ventricular wall thickness, and a higher risk for heart failure, cardiovascular death, and all-cause mortality. These findings suggest the need to develop amyloidosis screening strategies for V122I TTR carriers. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
35. Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018.
- Author
-
Salah, Husam M., Minhas, Abdul Mannan Khan, Khan, Muhammad Shahzeb, Khan, Safi U., Ambrosy, Andrew P., Blumer, Vanessa, Vaduganathan, Muthiah, Greene, Stephen J., Pandey, Ambarish, and Fudim, Marat
- Abstract
Aim: To determine the trends in hospitalizations for heart failure (HF), acute myocardial infarction (AMI), and stroke in the United States (US).Method and Results: A retrospective analysis of the National Inpatient Sample weighted data between January 1, 2004 and December 31, 2018 which included hospitalized adults ≥18 years with a primary discharge diagnosis of HF, AMI, or stroke using International Classification of Diseases-9/10 administrative codes. Main outcomes were hospitalization for HF, AMI, and stroke per 1000 United States adults, length of stay, and in-hospital mortality. There were 33.4 million hospitalizations for HF, AMI, and stroke, with most being for HF (48%). After the initial decline in HF hospitalizations (5.3 hospitalizations/1000 US adults in 2004 to 4 hospitalizations/1000 US adults in 2013, P < .001), there was a progressive increase in HF hospitalizations between 2013 and 2018 (4.0 hospitalizations/1000 US adults in 2013 to 4.9 hospitalizations/1000 US adults in 2018; P < .001). Hospitalization for AMI decreased (3.1 hospitalizations/1000 US adults in 2004 to 2.5 hospitalizations/1000 US adults in 2010, P < .001) and remained stable between 2010 and 2018. There was no significant change for hospitalization for stroke between 2004 and 2011 (2.3 hospitalizations/1000 US adults in 2004 vs 2.3 hospitalizations per 1000 US adults in 2011, P = .614); however, there was a small but significant increase in hospitalization for stroke after 2011 that reached 2.5 hospitalizations/1000 US adults in 2018. Adjusted length of stay and in-hospital mortality decreased for HF, AMI, and stroke hospitalizations.Conclusions: In contrast to the trend of AMI and stroke hospitalizations, a progressive increase in hospitalizations for HF has occurred since 2013. From 2004 to 2018, in-hospital mortality has decreased for HF, AMI, and stroke hospitalizations. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
36. Patient characteristics, care patterns, and outcomes of atrial fibrillation associated hospitalizations in patients with chronic kidney disease and end-stage renal disease.
- Author
-
Kumar, Nilay, Xu, Haolin, Garg, Neetika, Pandey, Ambarish, Matsouaka, Roland A, Field, Michael E, Turakhia, Mintu P, Piccini, Jonathan P, Lewis, William R, and Fonarow, Gregg C
- Abstract
Chronic Kidney Disease (CKD) and end-stage renal disease (ESRD) are associated with poor outcomes in patients with cardiovascular disease. There is a paucity of contemporary data on in-hospital outcomes and care patterns of atrial fibrillation (AF) associated hospitalizations CKD and ESRD. Outcomes and care patterns were evaluated in GWTG-AFIB database (Jan 2013-Dec 2018), including in-hospital mortality, use of a rhythm control strategy, and oral anticoagulation (OAC) prescription at discharge among eligible patients. Generalized logistic regression models with generalized estimating equations were used to ascertain differences in outcomes. Hospital-level variation in OAC prescription and rhythm control was also evaluated. Among 50,154 patients from 105 hospitals the median age was 70 years (interquartile range 61-79) and 47.3% were women. The prevalence of CKD was 36.0% while that of ESRD was 1.6%. Among eligible patients, discharge OAC prescription rates were 93.6% for CKD and 89.1% for ESRD. After adjustment, CKD and ESRD were associated with higher in-hospital mortality (odds ratio [OR] 3.08, 95% confidence interval [CI] 1.57-6.03 for ESRD and OR 2.02, 95% CI 1.52-2.67 for CKD), lower odds of OAC prescription at discharge (OR 0.59, 95% CI 0.44-0.79 for ESRD and OR 0.84, 95% CI 0.75-0.94 for CKD) compared with normal renal function. CKD was associated with lower utilization of rhythm control strategy (OR 0.92, 95% CI 0.87-0.98) with no significant difference between ESRD and normal renal function (OR 1.32, 95% CI 0.79-1.11). There was large hospital-level variation in OAC prescription at discharge (MOR 2.34, 95% CI 2.05-2.76) and utilization of a rhythm control strategy (MOR 2.69, 95% CI 2.34-3.21). CKD/ESRD is associated with higher in-hospital mortality, less frequent rhythm control, and less OAC prescription among patients hospitalized for AF. There is wide hospital-level variation in utilization of a rhythm control strategy and OAC prescription at discharge highlighting potential opportunities to improve care and outcomes for these patients, and better define standards of care in this patient population [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. Deep-Learning Models for the Echocardiographic Assessment of Diastolic Dysfunction.
- Author
-
Pandey, Ambarish, Kagiyama, Nobuyuki, Yanamala, Naveena, Segar, Matthew W., Cho, Jung S., Tokodi, Márton, and Sengupta, Partho P.
- Abstract
The authors explored a deep neural network (DeepNN) model that integrates multidimensional echocardiographic data to identify distinct patient subgroups with heart failure with preserved ejection fraction (HFpEF). The clinical algorithms for phenotyping the severity of diastolic dysfunction in HFpEF remain imprecise. The authors developed a DeepNN model to predict high- and low-risk phenogroups in a derivation cohort (n = 1,242). Model performance was first validated in 2 external cohorts to identify elevated left ventricular filling pressure (n = 84) and assess its prognostic value (n = 219) in patients with varying degrees of systolic and diastolic dysfunction. In 3 National Heart, Lung, and Blood Institute–funded HFpEF trials, the clinical significance of the model was further validated by assessing the relationships of the phenogroups with adverse clinical outcomes (TOPCAT [Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function] trial, n = 518), cardiac biomarkers, and exercise parameters (NEAT-HFpEF [Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction] and RELAX-HF [Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure] pooled cohort, n = 346). The DeepNN model showed higher area under the receiver-operating characteristic curve than 2016 American Society of Echocardiography guideline grades for predicting elevated left ventricular filling pressure (0.88 vs. 0.67; p = 0.01). The high-risk (vs. low-risk) phenogroup showed higher rates of heart failure hospitalization and/or death, even after adjusting for global left ventricular and atrial longitudinal strain (hazard ratio [HR]: 3.96; 95% confidence interval [CI]: 1.24 to 12.67; p = 0.021). Similarly, in the TOPCAT cohort, the high-risk (vs. low-risk) phenogroup showed higher rates of heart failure hospitalization or cardiac death (HR: 1.92; 95% CI: 1.16 to 3.22; p = 0.01) and higher event-free survival with spironolactone therapy (HR: 0.65; 95% CI: 0.46 to 0.90; p = 0.01). In the pooled RELAX-HF/NEAT-HFpEF cohort, the high-risk (vs. low-risk) phenogroup had a higher burden of chronic myocardial injury (p < 0.001), neurohormonal activation (p < 0.001), and lower exercise capacity (p = 0.001). This publicly available DeepNN classifier can characterize the severity of diastolic dysfunction and identify a specific subgroup of patients with HFpEF who have elevated left ventricular filling pressures, biomarkers of myocardial injury and stress, and adverse events and those who are more likely to respond to spironolactone. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review.
- Author
-
Pandey, Ambarish, Shah, Sanjiv J., Butler, Javed, Kellogg, Dean L., Lewis, Gregory D., Forman, Daniel E., Mentz, Robert J., Borlaug, Barry A., Simon, Marc A., Chirinos, Julio A., Fielding, Roger A., Volpi, Elena, Molina, Anthony J.A., Haykowsky, Mark J., Sam, Flora, Goodpaster, Bret H., Bertoni, Alain G., Justice, Jamie N., White, James P., and Ding, Jingzhone
- Subjects
- *
VENTRICULAR ejection fraction , *OLDER people , *CARDIOVASCULAR diseases , *HEART failure , *DRUG target , *EXERCISE tolerance , *HEART diseases , *ANIMALS - Abstract
Exercise intolerance (EI) is the primary manifestation of chronic heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure among older individuals. The recent recognition that HFpEF is likely a systemic, multiorgan disorder that shares characteristics with other common, difficult-to-treat, aging-related disorders suggests that novel insights may be gained from combining knowledge and concepts from aging and cardiovascular disease disciplines. This state-of-the-art review is based on the outcomes of a National Institute of Aging-sponsored working group meeting on aging and EI in HFpEF. We discuss aging-related and extracardiac contributors to EI in HFpEF and provide the rationale for a transdisciplinary, "gero-centric" approach to advance our understanding of EI in HFpEF and identify promising new therapeutic targets. We also provide a framework for prioritizing future research, including developing a uniform, comprehensive approach to phenotypic characterization of HFpEF, elucidating key geroscience targets for treatment, and conducting proof-of-concept trials to modify these targets. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. Hepatocyte Growth Factor and Incident Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA).
- Author
-
Ferraro, Richard A., Ogunmoroti, Oluseye, Zhao, Di, Ndumele, Chiadi E., Rao, Vishal, Pandey, Ambarish, Larson, Nicholas B., Bielinski, Suzette J., and Michos, Erin D.
- Abstract
Background: Hepatocyte growth factor (HGF) is a cytokine and marker of cardiovascular disease (CVD) risk. Less is known about HGF and incident heart failure (HF). We examined the association of HGF with incident HF and its subtypes in a multiethnic cohort.Methods and Results: We included 6597 participants of the Multi-Ethnic Study of Atherosclerosis (MESA) cohort, free of clinical CVD and HF at baseline, with HGF measured at baseline. Incident hospitalized HF was assessed and adjudicated for HF with preserved ejection fracture (HFpEF) vs HF with reduced ejection fraction (HFrEF). Cox regression models estimated hazard ratios (HR) and 95% confidence intervals (CI) for HF risk by HGF levels, adjusted for socio-demographics, CVD risk factors and N-terminal pro-B-type natriuretic peptide. The mean age was 62 ± 10 years. The median HGF level was 950 pg/mL (interquartile range, 758-1086 pg/mL); 53% were women. Over 14 years (IQR, 11.5-14.7 years), there were 324 cases of HF (133 HFpEF and 157 HFrEF). For the highest HGF tertile compared with lowest, adjusted HRs were 1.59 (95% CI, 1.10-2.31), 1.90 (95% CI, 1.03-3.51), and 1.09 (95% CI, 0.65-1.82) for overall HF, HFpEF, and HFrEF, respectively. For continuous analysis per 1-standard deviation log-transformed HGF, adjusted HRs were 1.22 (95% CI, 1.06-1.41), 1.35 (95% CI, 1.09-1.69), and 1.00 (95% CI, 0.81-1.24) for HF, HFpEF, and HFrEF, respectively.Conclusions: HGF was independently associated with incident HF. HGF remained significantly associated with HFpEF but not HFrEF upon subtype assessment. Future studies should examine the mechanisms underlying these associations and evaluate whether HGF can be used to improve HF risk prediction or direct therapy. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
40. Regional adiposity, cardiorespiratory fitness, and left ventricular strain: an analysis from the Dallas Heart Study.
- Author
-
Kondamudi, Nitin, Thangada, Neela, Patel, Kershaw V., Ayers, Colby, Chandra, Alvin, Berry, Jarret D., Neeland, Ian J., and Pandey, Ambarish
- Subjects
EXERCISE tests ,PHOTON absorptiometry ,CARDIOPULMONARY fitness ,LEFT ventricular dysfunction ,MULTIVARIATE analysis ,TREADMILLS ,MAGNETIC resonance imaging ,REGRESSION analysis ,BODY mass index ,ADIPOSE tissues ,HEART failure - Abstract
Background: Low cardiorespiratory fitness (CRF), high body mass index, and excess visceral adiposity are each associated with impairment in left ventricular (LV) peak circumferential strain (E
cc ), an intermediate phenotype that precedes the development of clinical heart failure (HF). However, the association of regional fat distribution and CRF with Ecc independent of each other and other potential confounders is not known. Methods: Participants from the Dallas Heart Study Phase 2 who underwent dual energy X-ray absorptiometry assessment of regional fat distribution, CRF assessment by submaximal treadmill test, and Ecc quantification by tissue-tagged cardiovascular magnetic resonance were included in the analysis. The cross-sectional associations of measures of regional adiposity, namely visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and lower-body fat (LBF) with Ecc after adjustment for CRF and other potential confounders (independent variables) were assessed using multivariable linear regression analysis. Results: The study included 1089 participants (55% female, 39% black). In the unadjusted analysis, higher VAT was associated with greater impairment in Ecc. After adjustment for baseline risk factors, CRF, parameters of LV structure and function, and other fat depots such as SAT and LBF, higher VAT remained associated with greater impairment in Ecc (β: 0.19, P = 0.002). SAT and LBF were not significantly associated with Ecc, however, CRF remained associated with Ecc in the fully adjusted model including all fat depots (β: - 0.15, P < 0.001). Conclusions: VAT and CRF are each independently associated with impairment in Ecc , suggesting that higher VAT burden and low CRF mediate pathological cardiac remodeling through distinct mechanisms. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
41. DIGITAL HEALTH LITERACY AMONG INDIVIDUALS WITH CARDIOVASCULAR DISEASES ACROSS SOCIAL DETERMINANTS OF HEALTH IN 2011-2018.
- Author
-
Nagori, Aditya, Pandey, Ambarish, and Sumarsono, Andrew
- Subjects
- *
HEALTH literacy , *DIGITAL literacy , *SOCIAL determinants of health , *DIGITAL health , *CARDIOVASCULAR diseases - Published
- 2024
- Full Text
- View/download PDF
42. DEMOGRAPHIC DIFFERENCES IN PREVALENCE AND OUTCOMES OF OBSTRUCTIVE VS. NON-OBSTRUCTIVE CORONARY ARTERY DISEASE IN PATIENTS ADMITTED WITH ACUTE DECOMPENSATED HEART FAILURE.
- Author
-
Chunawala, Zainali, Pandey, Ambarish, Qamar, Arman, Fudim, Marat, Vaduganathan, Muthiah, Mentz, Robert John, Bhatt, Deepak L., and Caughey, Melissa
- Subjects
- *
CORONARY artery disease , *DEMOGRAPHIC characteristics , *HEART failure - Published
- 2024
- Full Text
- View/download PDF
43. Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure.
- Author
-
Fudim, Marat, Lerman, Joseph B., Page, Courtney, Alhanti, Brooke, Califf, Robert M., Ezekowitz, Justin A., Girerd, Nicolas, Grodin, Justin L., Miller, Wayne L., Pandey, Ambarish, Rossignol, Patrick, Starling, Randall C., Tang, W.H. Wilson, Zannad, Faiez, Hernandez, Adrian F., O'connor, Christopher M., and Mentz, Robert J.
- Abstract
Background: Prior analyses suggest an association between formula-based plasma volume (PV) estimates and outcomes in heart failure (HF). We assessed the association between estimated PV status by the Duarte-ePV and Kaplan Hakim (KH-ePVS) formulas, and in-hospital and postdischarge clinical outcomes, in the ASCEND-HF trial.Methods and Results: The KH-ePVS and Duarte-ePV were calculated on admission. We assessed associations with in-hospital worsening HF, 30-day composite cardiovascular mortality or HF rehospitalization and 180-day all-cause mortality. There were 6373 (89.2%), and 6354 (89.0%) patients who had necessary characteristics to calculate KH-ePVS and Duarte-ePV, respectively. There was no association between PV by either formula with in-hospital worsening HF. KH-ePVS showed a weak correlation with N-terminal prohormone BNP, and with measures of decongestion such as body weight change and urine output (r < 0.3 for all). Duarte-ePV was trending toward an association with worse 30-day (adjusted odds ratio 1.07, 95% confidence interval [CI] 1.00-1.15, P = .058), but not 180-day outcomes (adjusted hazard ratio 1.03, 95% CI 0.97-1.09, P = .289). A continuous KH-ePVS of >0 (per 10-unit increase) was associated with improved 30-day outcomes (adjusted odds ratio 0.75, 95% CI 0.62-0.91, P = .004). The continuous KH-ePVS was not associated with 180-day outcomes (adjusted hazard ratio 1.05, 95% CI 0.98-1.12, P = .139).Conclusions: Baseline PV estimates had a weak association with in-hospital measures of decongestion. The Duarte-ePV trended toward an association with early clinical outcomes in decompensated HF, and may improve risk stratification in HF. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
44. Running away from cardiovascular disease at the right speed: The impact of aerobic physical activity and cardiorespiratory fitness on cardiovascular disease risk and associated subclinical phenotypes.
- Author
-
Mehta, Anurag, Kondamudi, Nitin, Laukkanen, Jari A., Wisloff, Ulrik, Franklin, Barry A., Arena, Ross, Lavie, Carl J., and Pandey, Ambarish
- Abstract
Higher levels of physical activity (PA) and cardiorespiratory fitness (CRF) are associated with lower risk of incident cardiovascular disease (CVD). However, the relationship of aerobic PA and CRF with risk of atherosclerotic CVD outcomes and heart failure (HF) seem to be distinct. Furthermore, recent studies have raised concerns of potential toxicity associated with extreme levels of aerobic exercise, with higher levels of coronary artery calcium and incident atrial fibrillation noted among individuals with very high PA levels. In contrast, the relationship between PA levels and measures of left ventricular structure and function and risk of HF is more linear. Thus, personalizing exercise levels to optimal doses may be key to achieving beneficial outcomes and preventing adverse CVD events among high risk individuals. In this report, we provide a comprehensive review of the literature on the associations of aerobic PA and CRF levels with risk of adverse CVD outcomes and the preceding subclinical cardiac phenotypes to better characterize the optimal exercise dose needed to favorably modify CVD risk. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
45. Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure.
- Author
-
Singh, Shruti, Pandey, Ambarish, and Neeland, Ian J.
- Abstract
Natriuretic peptides (NPs, B-type natriuretic peptide /BNP and NT-proBNP) are universally used biomarkers with established cut-points to aid in the diagnosis of heart failure (HF). It has been demonstrated that an inverse relationship exists between obesity, defined by the body mass index (BMI), and NPs, such that the application of NPs to diagnostic algorithms in HF remains challenging in overweight and obese patients. Some have advocated that lowering the cut-offs for NPs or using a correction for high BMI may improve the diagnostic accuracy in obese individuals. The inverse relationship of NPs with high BMI is present in both HF with reduced (HFrEF) and with preserved (HFpEF) ejection fraction, although levels tend to be higher in HFrEF. Nevertheless, data from several studies have shown that the prognostic value of NPs is preserved across BMI classes, and that increasing circulating levels of NPs correlate with adverse outcomes including all-cause mortality and HF hospitalizations. While NPs can still be used in diagnosis of HF in obese individuals, lower thresholds and the clinical context should be utilized in decision making. Additionally, given the validated prognostic value even in obesity, NPs can be employed in risk-stratification of individuals with obesity and HF, although there remains limited evidence about use in those with severe obesity (BMI >40 kg/m2). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
46. Resistant hypertension-defining the scope of the problem.
- Author
-
Chia, Richard, Pandey, Ambarish, and Vongpatanasin, Wanpen
- Abstract
The updated scientific statement by the American Heart Association has defined resistant hypertension (HTN;RH) as uncontrolled blood pressure (BP) ≥ 130/80 mmHg, despite concurrent use of 3 anti-HTN drug classes comprising a calcium channel blocker, a blocker of renin-angiotensin system, and a thiazide diuretic, preferably chlorthalidone. Using the updated BP criteria, the prevalence of RH in the United States is found to be modestly increased by approximately 3-4% among treated population. Meta-analysis of observational studies have demonstrated that pseudo-RH from white coat HTN or medication nonadherence is as much common as the truly RH. Thus, screening for pseudo-resistance in the evaluation of all apparent RH is of utmost importance as diagnosis of white-coat HTN requires no treatment, while medication nonadherence would benefit from identifying and targeting barriers to adherence. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
47. "Working Me To Life" - Longitudinal Perceptions From Adults With Heart Failure With Preserved Ejection Fraction Enrolled In An Exercise Clinical Trial.
- Author
-
Alonso, Windy W., Salahshurian, Erin, Pandey, Ambarish, Carbone, Salvatore, Lundgren, Scott, and Pozehl, Bunny
- Abstract
This study explored the longitudinal perceptions of adults with heart failure with preserved ejection fraction (HFpEF) enrolled in the intervention arm of an 18-month exercise clinical trial of adults with chronic, stable heart failure (n=204). Adults with HFpEF responded more favorably to the intervention with significantly improved long-term adherence to exercise (>120 minutes/week) compared to those with reduced ejection fraction. We sought to better understand what contributed to this response. This qualitative descriptive study is a secondary analysis of longitudinal qualitative interviews collected during a multisite, 2-arm, randomized controlled trial of a coaching intervention to promote long-term (18 months) adherence to exercise in adults with heart failure. In the parent study, participants (n=102) in the intervention arm were interviewed at 3, 6, 12, and 18 months to gain a better understanding of experiences with exercise including barriers and facilitators. This secondary analysis included only participants with HFpEF with ≥2 interviews. Interviews were examined across participants and across time points using qualitative content analysis to develop codes that were compiled into major themes. Of the 27 adults with HFpEF enrolled in the intervention arm, 21 had at least 2 interviews. Our sample was 52% (11/21) male and over 47% (10/21) Black or African American. Mean age at enrollment was 63.7 ± 9.9 years. We identified 5 major themes across participants and time points including: 1. Overcoming misconceptions and attitudes - "I didn't think I could exercise. I've been proven wrong." Most participants expressed initial fears or poor attitudes toward exercise that changed over time. 2. The exercise coach is the key ingredient - "[Coach] is working me to life." Participants praised coaches at all interview times as key accountability partners for their success. 3. Exercise - the panacea for HFpEF symptoms and quality of life - "The more I exercise, the better I feel about everything." Most participants expressed relief of physical and emotional symptoms with continued exercise. 4. Unmotivated to Exercise - "[Exercise] was not worth the effort" - Participants that did not participate in exercise often expressed lack of motivation or not feeling well after exercise at all time points. From the participants that actively participated in the intervention, we found our final theme - 5. Advice for others with HFpEF - "Give exercise a chance. It gets better." Most participants expressed confidence to continue with exercise after the study and extended their gym membership or joined another exercise facility. Most adults with HFpEF expressed benefits from participating in an exercise clinical trial including symptom relief, improved quality of life and attitudes toward exercise, and increased motivation as they continued in the study. Some participants did not actively participate and unsurprisingly, these same participants did not perceive the benefits to exercise or experience improvements in negative attitudes or motivation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Managing Implantable Cardioverter-Defibrillators at End-of-Life: Practical Challenges and Care Considerations.
- Author
-
Khera, Rohan, Pandey, Ambarish, Link, Mark S., and Sulistio, Melanie S.
- Published
- 2019
- Full Text
- View/download PDF
49. Association of Non-Alcoholic Fatty Liver Disease With in-Hospital Outcomes in Primary Heart Failure Hospitalizations With Reduced or Preserved Ejection Fraction.
- Author
-
Minhas, Abdul Mannan Khan, Bhopalwala, Huzefa M., Dewaswala, Nakeya, Salah, Husam M., Khan, Muhammad Shahzeb, Shahid, Izza, Biegus, Jan, Lopes, Renato D., Pandey, Ambarish, and Fudim, Marat
- Abstract
Recent studies focusing on the prevalence, characteristics, and outcomes of primary heart failure (HF) with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF) in non-alcoholic fatty liver disease (NAFLD) are sparse. We sought to assess these using a nationally-representative population. We used the 2016-2018 National Inpatient Sample database to study the prevalence, characteristics, clinical risk profiles, morbidity, mortality, cost, and resource utilization among primary HFpEF and HFrEF hospitalizations with and without NAFLD. In the period from January 1, 2016, to December 31, 2018, there were 3,522,459 admissions of patients aged ≥18 years with a diagnosis of primary HF. Of these, 82,585 (2.3%) hospitalizations had secondary diagnosis of NAFLD. Admissions with NAFLD and HFrEF were associated with higher rates of in-hospital mortality (aOR 1.84, CI 1.66-2.04, P < 0.001) compared to admissions of HFrEF without NAFLD. Similarly, hospitalizations with HFpEF-NAFLD were associated with higher rates of in hospital mortality (aOR 1.65 CI 1.43-1.9, P < 0.001) compared to HFpEF admissions without NAFLD. Pressors use, cardiogenic shock, AKI with or without dialysis use, cardiac arrest, LOS and hospitalization cost were higher in admissions of HFrEF and HFpEF with NAFLD compared to those without NAFLD. In-hospital mortality, was higher in primary HFrEF and HFpEF admissions with NAFLD compared to without NAFLD. Physicians must be aware of the worse clinical outcomes of HFrEF and HFpEF in patients with NAFLD. Further clinical research is needed to address the knowledge gap and treatment options available for the patients with HF and NAFLD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. Neighborhood-level Social Vulnerability and Prevalence of Cardiovascular Risk Factors and Coronary Heart Disease.
- Author
-
Bevan, Graham, Pandey, Ambarish, Griggs, Stephanie, Dalton, Jarrod E., Zidar, David, Patel, Shivani, Khan, Safi U, Nasir, Khurram, Rajagopalan, Sanjay, and Al-Kindi, Sadeer
- Abstract
Social determinants of health are implicated in the geographic variation in cardiovascular diseases (CVDs). The social vulnerability index (SVI) is an estimate of a neighborhood's potential for deleterious outcomes when faced with natural disasters or disease outbreaks. We sought to investigate the association of the SVI with cardiovascular risk factors and the prevalence of coronary heart disease (CHD) in the United States at the census tract level. We linked census tract SVI with prevalence of census tract CVD risk factors (smoking, high cholesterol, diabetes, high blood pressure, low physical activity and obesity), and prevalence of CHD obtained from the behavioral risk factor surveillance system. We evaluated the association between SVI, its sub-scales, CVD risk factors and CHD prevalence using linear regression. Among 72,173 census tracts, prevalence of all cardiovascular risk factors increased linearly with SVI. A higher SVI was associated with a higher CHD prevalence (R
2 = 0.17, P < 0.0001). The relationship between SVI and CHD was stronger when accounting for census-tract median age (R2 = 0.57, P < 0.0001). A multivariable linear regression model including 4 SVI themes separately explained considerably more variation in CHD prevalence than the composite SVI alone (50.0% vs 17.3%). Socioeconomic status and household composition and disability were the SVI themes most closely associated with cardiovascular risk factors and CHD prevalence. In the United States, social vulnerability can explain significant portion of geographic variation in CHD, and its risk factors. Neighborhoods with high social vulnerability are at disproportionately increased risk of CHD and its risk factors. Social determinants of health are implicated in the geographic variation in cardiovascular diseases (CVDs). We investigated the association of social vulnerability index (SVI) with cardiovascular risk factors and the prevalence of coronary heart disease (CHD) in the United States at the census tract level. We show that cardiovascular risk factors and CHD were more common with higher SVI. A multivariable linear regression model including 4 SVI themes separately explained considerably more variation in CHD prevalence than the composite SVI alone (50.0% vs 17.3%). Socioeconomic status and household composition and/or disability were the SVI themes most closely associated with cardiovascular risk factors and CHD prevalence. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.